Auf dieser Seite
PVLA Palvella Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 4, 2026
$132,47
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$61,7352-Wochen-Tief
$161,3852-Wochen-Hoch
Marktkapitalisierung (MRQ)
$1.91B
P/E
-35.7
EPS
$-3.71
Umsatz
$43M
Ihre Abzeichen
52W-Spanne
$62–$161
Analystenbewertung
BUY
Kursziel
$231
P/E
-35.7
ROE
-110.1%
Nettogewinnmarge
-1610.6%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
PVLA Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$132.47
Marktkapitalisierung (MRQ)
$1.91B
P/E
-35.7
EPS
$-3.71
Umsatz
$43M
ROE
-110.1%
52W-Spanne
$62–$161
PVLA Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 23. April 2024 | 1-for-80 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$43M2017-12-31 → 2023-12-31
EPS$-3.712020-12-31 → 2025-12-31
Freier Cashflow·2017-12-31 → 2022-12-31
Nettogewinnmarge-1610.6%2017-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | PVLA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -35.75-Jahres-Durchschnitt ≈-113.6 | ≈-113.6 | · | · | |
| P/S | 83.85-Jahres-Durchschnitt ≈104.1 | ≈104.1 | 25.9 | Überbewertet | |
| K/B (MRQ) | 8.85-Jahres-Durchschnitt ≈90.1 | ≈90.1 | 5.4 | Überbewertet | |
| Price / Cash Flow (Kurs / Cashflow) | -65.65-Jahres-Durchschnitt ≈-55.8 | ≈-55.8 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 58.65-Jahres-Durchschnitt ≈159.6 | ≈159.6 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | PVLA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Operating Margin (Betriebsgewinnmarge) | -1490.4% | · | -668.2% | Unterdurchschnittlich | |
| EBITDA Margin (EBITDA-Marge) | -1490.4% | · | -668.2% | Unterdurchschnittlich | |
| Pretax Margin (Vorgewinnmarge) | -1610.6% | · | -765.9% | Schwach | |
| Net Profit Margin (Nettogewinnmarge) | -1610.6% | · | -669.0% | Unterdurchschnittlich | |
| ROA | -56.5%5-Jahres-Durchschnitt ≈-39.9% | ≈-39.9% | -42.9% | Schwach | |
| ROE | -110.1%5-Jahres-Durchschnitt ≈-20.5% | ≈-20.5% | -60.0% | Schwach | |
| ROIC | -137.9%5-Jahres-Durchschnitt ≈-105.4% | ≈-105.4% | -62.3% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | PVLA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 21.25-Jahres-Durchschnitt ≈4.8 | ≈4.8 | 6.0 | Starke Liquidität | |
| Quick Ratio | 5.15-Jahres-Durchschnitt ≈4.6 | ≈4.6 | 4.4 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | PVLA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 65.3%5-Jahres-Durchschnitt ≈18.3% | ≈18.3% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 13.4% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | PVLA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.0 | · | 0.1 | Schwach | |
| Receivables Turnover (Forderungsumschlag) | 14.5 | · | 4.6 | Spitzenklasse | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$1.5M | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-53.9%
Nächster Bericht
Nov 09, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 13, 2026 | $-1.52 | $-1.18 | -28.5% |
| 31. März 2026 | Mai 14, 2026 | $-1.20 | $-0.95 | -26.2% |
| 31. Dezember 2025 | $-1.07 | $-0.93 | -15.2% | |
| 30. September 2025 | $-1.03 | $-0.86 | -20.5% | |
| 30. Juni 2025 | $-0.86 | $-0.76 | -13.8% | |
| 31. März 2025 | $-0.74 | $-1.24 | 40.1% | |
| 31. Dezember 2024 | $-2.72 | $-0.66 | -313.4% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $43M | $26M | $31M | $29M | $46M | $29M | $25M | $6M | $3M | $5M | |
| R&D Expense | $23M | $8M | $9M | $53M | $67M | $47M | $55M | $41M | $22M | $20M | $8M | $6M | |
| SG&A Expense | $16M | $6M | $3M | $16M | $17M | $17M | $18M | $18M | $18M | $9M | $8M | $7M | |
| Operating Expenses | $39M | $14M | $12M | $69M | $83M | $63M | $73M | $60M | $40M | $29M | $17M | $13M | |
| Operating Income | $-39M | $-14M | $-12M | $-43M | $-52M | $-34M | $-27M | $-31M | $-15M | $-23M | $-14M | $-7M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Other Non-op | $727.0K | $-131.0K | $712.0K | $1M | $2M | $-4M | $-26.0K | $2M | $-2M | $120.0K | $10.9K | $3.0K | |
| Pretax Income | $-42M | $-17M | $19M | $-33M | $-46M | $-37M | $-25M | $-27M | $-17M | $-23M | $-14M | $-10M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $164.0K | $0 | $-312.0K | $1M | $162.0K | $203.9K | $-18 | |
| Net Income | $-42M | $-17M | $19M | $-33M | $-46M | $-37M | $-25M | $-27M | $-18M | $-23M | $-14M | $-10M | |
| EPS (Basic) | $-3.71 | $-7.83 | $2.19 | $-0.45 | $-0.71 | $-0.68 | · | · | · | · | · | · | |
| EPS (Diluted) | $-3.71 | $-7.83 | $2.17 | · | $-0.71 | $-0.68 | · | · | · | · | · | · | |
| Shares (Basic) | 11,251,250 | 2,225,934 | 1,770,167 | 74,172,000 | 64,547,000 | 54,481,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 11,251,250 | 2,225,934 | 1,793,980 | · | 64,547,000 | 54,481,000 | · | · | · | · | · | · | |
| EBITDA | $-39M | $-14M | · | $-41M | · | $-34M | $-27M | $-31M | $-15M | · | · | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $84M | $7M | $39M | $118M | $70M | $62M | $75M | $38M | $29M | $29M | $18M | |
| Short-term Investments | $0 | · | $9M | $21M | $0 | $0 | $42M | $53M | $35M | $0 | · | · | |
| Receivables | $0 | $358.0K | $0 | $6M | $3M | $2M | $7M | $3M | $16M | $57.0K | $0 | $0 | |
| Prepaid Expense | $1M | $2M | $198.0K | $3M | $7M | $4M | $4M | $5M | $2M | $3M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $59M | $88M | $8M | $73M | $128M | $76M | $115M | $135M | $90M | $33M | $32M | $20M | |
| PP&E (Net) | · | · | $0 | $17M | $19M | $22M | $20M | $5M | $4M | $2M | $2M | $2M | |
| PP&E (Gross) | · | · | · | $27M | $27M | $28M | $23M | $8M | $7M | $5M | $4M | $4M | |
| Accum. Depreciation | · | · | · | $10M | $8M | $6M | $4M | $3M | $3M | $2M | $2M | $2M | |
| Other Non-current Assets | · | · | $0 | $1M | $3M | $3M | $3M | $910.0K | $130.0K | $126.0K | $126.8K | · | |
| Total Assets | $60M | $88M | $8M | $95M | $154M | $105M | $141M | $141M | $104M | $35M | $34M | $22M | |
| Accounts Payable | $5M | $5M | $936.0K | $4M | $9M | $2M | $6M | $3M | $2M | $2M | $1M | · | |
| Accrued Liabilities | · | · | · | · | · | $8M | $10M | $9M | $6M | $4M | $2M | $986.6K | |
| Current Liabilities | $11M | $12M | $2M | $37M | $51M | $22M | $27M | $48M | $46M | $8M | $3M | $4M | |
| Capital Leases | $431.0K | $0 | $0 | $12M | $14M | $16M | $15M | $0 | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | $0 | $0 | $6.0K | $0 | $27.0K | $37.0K | $47.0K | $23.9K | $334.0K | |
| Total Liabilities | $32M | $26M | $11M | $68M | $103M | $74M | $90M | $101M | $92M | $10M | $3M | $4M | |
| Common Stock | $12.0K | $11.0K | $0 | $74.0K | $72.0K | $56.0K | $55.0K | $54.0K | $45.0K | $43.0K | $39.8K | $29.3K | |
| Paid-in Capital | $163M | $156M | $2M | $319M | $307M | · | · | · | · | · | $112M | $85M | |
| Retained Earnings | $-135M | $-94M | $-76M | $-290M | $-257M | $-211M | $-174M | $-147M | $-120M | $-103M | $-80M | $-66M | |
| AOCI | $83.0K | $3.0K | $0 | $-254.0K | $829.0K | $-295.0K | $-2M | $-3M | $-5M | $-2M | $-1M | $-843.1K | |
| Stockholders' Equity | $28M | $63M | $-74M | $-94M | $51M | $31M | $51M | $40M | $12M | $25M | $31M | $18M | |
| Liabilities + Equity | $60M | $88M | $8M | $95M | $154M | $105M | $141M | $141M | $104M | $35M | $34M | $22M | |
| Shares Outstanding | 12,380,933 | 11,012,105 | 1,770,167 | 74,519,103 | 72,222,661 | 56,003,000 | 55,212,437 | 54,151,219 | 45,017,062 | 43,058,827 | 39,833,023 | 29,279,522 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $2M | $3M | $2M | · | · | · | · | · | · | · | |
| Stock-based Comp | $6M | $830.0K | $603.0K | $4M | $5M | $5M | $5M | $5M | $3M | $2M | $1M | $571.4K | |
| Deferred Tax | · | · | $0 | $0 | $0 | $0 | $0 | $-164.0K | $0 | $0 | $0 | $0 | |
| Other Non-cash | · | · | · | $-34M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-25M | $-11M | $-14M | $-60M | $-8M | $-46M | $-52M | $-1M | $50M | $-14M | $-13M | $-5M | |
| CapEx | · | · | $171.0K | $1M | $949.0K | $3M | $2M | $2M | $2M | $560.0K | $620.7K | $267.4K | |
| Investing Cash Flow | · | · | $12M | $-21M | $-949.0K | $39M | $10M | $-9M | $-46M | · | · | · | |
| Stock Issued | · | · | $20M | $7M | $38M | $10M | · | · | · | · | $26M | $12M | |
| Net Stock Activity | · | · | · | $7M | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-660.0K | $87M | $5M | $7M | $59M | $10M | $32M | $49M | $4M | · | · | · | |
| Net Change in Cash | $-26M | $76M | $-9M | $-79M | $47M | $8M | $-13M | $37M | $9M | $6.0K | $11M | $15M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | · | $51.7K | |
| Free Cash Flow | · | · | · | $-61M | · | $-49M | $-55M | $-3M | $48M | · | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1490.4% | · | · | -167.8% | · | -115.7% | -58.7% | -105.9% | -57.7% | · | · | · | |
| Net Margin | -1610.6% | · | · | -128.5% | · | -127.0% | -55.0% | -91.9% | -69.8% | · | · | · | |
| Pretax Margin | -1610.6% | · | · | -128.5% | · | -126.4% | -55.0% | -93.0% | -65.5% | · | · | · | |
| EBITDA Margin | -1490.4% | · | · | -157.1% | · | -115.7% | -58.7% | -105.9% | -57.7% | · | · | · | |
| ROA | -56.5% | -36.4% | · | -26.7% | · | -30.3% | -17.9% | -21.8% | -25.4% | · | · | · | |
| ROE | -110.1% | 140.6% | · | -92.1% | · | -99.7% | -70.8% | -59.3% | -96.0% | · | · | · | |
| ROIC | -137.9% | -22.5% | · | -155.7% | · | -109.8% | -52.9% | -76.3% | -135.1% | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 7.3 | · | 2.0 | · | 3.4 | 4.3 | 2.8 | 2.0 | · | · | · | |
| Quick Ratio | 5.1 | 7.0 | · | 1.8 | · | 3.3 | 4.1 | 2.7 | 1.9 | · | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | 0.2 | · | 0.2 | 0.3 | 0.2 | 0.4 | · | · | · | |
| Receivables Turnover | 14.5 | · | · | 5.7 | · | 6.9 | 9.8 | 3.2 | 3.2 | · | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.26 | $5.69 | · | $0.37 | · | $0.55 | $0.93 | $0.74 | $0.26 | · | · | · | |
| Revenue / Share | $0.23 | · | · | · | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-2.22 | $-4.87 | · | · | · | · | · | · | · | · | · | · | |
| Cash / Share | $4.68 | $7.59 | · | $0.52 | · | $1.26 | $1.13 | $1.38 | $0.84 | · | · | · | |
| EPS (TTM) | $-3.71 | $-7.83 | $2.17 | $-0.70 | $-0.71 | $-0.68 | · | · | · | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | 65.3% | -17.6% | 7.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | · | · | 13.4% | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $20M | $20M | $43M | $26M | $31M | $29M | $46M | $29M | $25M | $6M | $3M | $5M | |
| Net Income TTM | $-42M | $-17M | $19M | $-33M | $-46M | $-37M | $-25M | $-27M | $-18M | $-23M | $-14M | $-10M | |
| Market Cap | $1.30B | $132M | · | $6.20B | · | $11.20B | $15.99B | $11.52B | $27.19B | · | · | · | |
| P/E | -28.2 | -1.5 | 6.7 | -118.9 | -425.9 | -294.1 | · | · | · | · | · | · | |
| P/S | 66.2 | 6.8 | · | 239.4 | · | 382.0 | 345.5 | 396.0 | 1075.8 | · | · | · | |
| P/B | 46.3 | 2.1 | · | 222.0 | · | 361.0 | 311.4 | 288.6 | 2359.9 | · | · | · | |
| P / Tangible Book | 46.3 | 2.1 | · | · | 430.3 | 361.0 | · | · | · | · | · | · | |
| P / Cash Flow | -51.8 | -12.2 | · | -103.5 | · | -244.0 | -304.8 | -10809.9 | 546.5 | · | · | · | |
| P / FCF | · | · | · | -101.7 | · | -230.4 | -291.1 | -4169.1 | 568.8 | · | · | · | |
| Earnings Yield | -3.5% | -65.2% | 14.9% | -0.84% | -0.23% | -0.34% | · | · | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | $0 | $0 | $53.0K | · | $20M | $20M | $2M | $6M | $5M | |
| R&D Expense | $12M | $9M | $7M | $7M | $5M | $4M | $3M | $3M | $1M | $984.0K | $-29M | $10M | $14M | $13M | $13M | $14M | |
| SG&A Expense | $9M | $6M | $4M | $4M | $4M | $4M | $2M | $2M | $1M | $775.0K | $-11M | $7M | $4M | $4M | $4M | $4M | |
| Operating Expenses | $21M | $15M | $11M | $10M | $9M | $8M | $4M | $5M | $3M | $2M | $-55M | $31M | $18M | $17M | $17M | $18M | |
| Operating Income | $-21M | $-15M | $-11M | $-10M | $-9M | $-8M | $-4M | $-5M | $-3M | $-2M | $13M | $-12M | $2M | $-16M | $-12M | $-12M | |
| Other Non-op | $-8.0K | $-32.0K | $-92.0K | $34.0K | $561.0K | $224.0K | $-175.0K | $-20.0K | $64.0K | $0 | $424.0K | $506.0K | $-161.0K | $-57.0K | $-325.0K | $723.0K | |
| Pretax Income | $-22M | $-16M | $-13M | $-11M | $-9M | $-8M | $-4M | $-7M | $-4M | $-3M | · | · | · | · | · | · | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Income | $-22M | $-16M | $-13M | $-11M | $-9M | $-8M | $-4M | $-7M | $-4M | $-3M | $39M | $-11M | $4M | $-13M | $-8M | $-10M | |
| EPS (Basic) | $-1.52 | $-1.20 | $-1.08 | $-1.03 | $-0.86 | $-0.74 | $0.12 | $-3.94 | $-2.47 | $-1.54 | $21.41 | $-8.70 | $3.63 | $-14.15 | $-0.11 | $-0.13 | |
| EPS (Diluted) | $-1.52 | $-1.20 | $-1.08 | $-1.03 | $-0.86 | $-0.74 | $0.12 | $-3.94 | $-2.47 | $-1.54 | $20.50 | $-8.70 | $3.62 | · | · | · | |
| Shares (Basic) | 14,356,219 | 13,085,271 | · | 11,064,282 | 11,052,741 | 11,013,697 | · | 1,770,167 | 1,770,167 | 1,770,167 | · | 1,236,000 | 1,095,000 | 931,000 | · | 74,397,000 | |
| Shares (Diluted) | 14,356,219 | 13,085,271 | · | 11,064,282 | 11,052,741 | 11,013,697 | · | 1,770,167 | 1,770,167 | 1,770,167 | · | 1,236,000 | 1,098,000 | · | · | · | |
| EBITDA | $-21M | $-15M | · | $-10M | $-9M | $-8M | · | $-3M | $-4M | $-5M | · | $-12M | $2M | $-15M | · | $-12M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $188M | $206M | $58M | $64M | $70M | $76M | $84M | $19M | $20M | $19M | $7M | $33M | $45M | $40M | $39M | $48M | |
| Short-term Investments | $63M | $55M | · | · | · | · | · | $0 | $0 | $0 | · | $12M | $10M | $9M | $21M | $21M | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $358.0K | $373.0K | $1M | $2M | $0 | $1M | $952.0K | $1M | $6M | $829.0K | |
| Prepaid Expense | $2M | $1M | $1M | $1M | $1M | $2M | $2M | $280.0K | $649.0K | $3M | $198.0K | $9M | $11M | $11M | $3M | $8M | |
| Current Assets | $253M | $263M | $59M | $67M | $74M | $79M | $88M | · | · | · | $8M | $59M | $66M | $61M | $73M | $79M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | $0 | $16M | $17M | $17M | $16M | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | $27M | $27M | $27M | $24M | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | · | $11M | $10M | $10M | $8M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | · | $287.0K | $1M | $1M | $1M | $1M | |
| Total Assets | $254M | $264M | $60M | $67M | $74M | $79M | $88M | $21M | $25M | $29M | $8M | $59M | $88M | $82M | $95M | $99M | |
| Accounts Payable | $7M | $5M | $5M | $3M | $5M | $4M | $5M | $801.0K | $969.0K | $2M | $936.0K | $3M | $8M | $6M | $4M | $4M | |
| Current Liabilities | $12M | $9M | $11M | $10M | $10M | $9M | $12M | $4M | $6M | $8M | $2M | $29M | $34M | $43M | $37M | $34M | |
| Capital Leases | $318.0K | $375.0K | $431.0K | · | · | · | $0 | · | · | · | · | $0 | $12M | $12M | $12M | $11M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Total Liabilities | $37M | $31M | $32M | $28M | $26M | $24M | $26M | · | · | · | $11M | $29M | $47M | $67M | $68M | $63M | |
| Common Stock | $14.0K | $14.0K | $12.0K | $11.0K | $11.0K | $11.0K | $11.0K | $1.0K | $1.0K | $1.0K | $0 | $99.0K | $99.0K | $74.0K | $74.0K | $74.0K | |
| Paid-in Capital | $390M | $383M | $163M | $161M | $159M | $157M | $156M | $343M | $343M | $342M | $2M | $341M | $340M | $319M | $319M | $317M | |
| Retained Earnings | $-173M | $-151M | $-135M | $-123M | $-111M | $-102M | $-94M | $-326M | $-323M | $-320M | $-76M | $-310M | $-300M | $-304M | $-290M | $-282M | |
| AOCI | $89.0K | $95.0K | $83.0K | $104.0K | $-111.0K | $-3.0K | $3.0K | $-316.0K | $-436.0K | $-346.0K | $0 | $-339.0K | $-137.0K | $-426.0K | $-254.0K | $524.0K | |
| Stockholders' Equity | $217M | $232M | $28M | $39M | $48M | $56M | $63M | $16M | $19M | $22M | $-74M | $31M | $40M | $15M | $28M | $36M | |
| Liabilities + Equity | $254M | $264M | $60M | $67M | $74M | $79M | $88M | $21M | $25M | $29M | $8M | $59M | $88M | $82M | $95M | $99M | |
| Shares Outstanding | 14,395,705 | 14,313,659 | 12,380,933 | 11,088,329 | 11,059,665 | 11,021,389 | 11,012,105 | 1,320,240 | 1,320,240 | 1,236,688 | 1,770,167 | · | 98,851,927 | 74,519,103 | 74,519,103 | 74,406,253 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $0 | $0 | $-30.0K | · | $739.0K | $758.0K | $605.0K | $575.0K | $767.0K | |
| Stock-based Comp | $5M | $3M | $2M | $2M | $1M | $1M | $268.0K | $-331.0K | $-109.0K | $146.0K | $-2M | $966.0K | $1M | $884.0K | $949.0K | $974.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-7M | · | · | · | $1M | · | · | |
| Operating Cash Flow | $-13M | $-11M | $-5M | $-8M | $-5M | $-7M | $-5M | $3M | $4M | $-1M | $20M | $-10M | $-13M | $-11M | $-13M | $-9M | |
| CapEx | · | · | · | · | · | · | · | $0 | $0 | $0 | · | $69.0K | $67.0K | $48.0K | $-11.0K | $34.0K | |
| Investing Cash Flow | $-7M | $-55M | · | · | $0 | $0 | · | $142.0K | $2M | $9M | · | $-2M | $-1M | $12M | $1M | $5M | |
| Stock Issued | $0 | $230M | · | · | $0 | $0 | · | $0 | · | · | · | $0 | $20M | $0 | $0 | $282.0K | |
| Net Stock Activity | · | $230M | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $1M | $215M | $-49.0K | $242.0K | $349.0K | $-1M | $75M | $12M | $10M | $0 | $-15M | $0 | $20M | $0 | $93.0K | $282.0K | |
| Net Change in Cash | $-19M | $148M | $-6M | $-7M | $-5M | $-8M | $69M | $5M | $5M | $-1M | $-3M | $-12M | $5M | $1M | $-10M | $-6M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-7M | · | · | · | $-11M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1089.3% | -1384.4% | · | -1620.5% | -1340.6% | -1046.7% | · | · | · | -10005.7% | · | -60.5% | 10.3% | -801.2% | · | -226.6% | |
| Net Margin | -1113.0% | -1469.4% | · | -1806.5% | -1372.6% | -1088.4% | · | · | · | -9230.2% | · | -55.1% | 19.8% | -680.9% | · | -181.3% | |
| Pretax Margin | -1113.0% | -1469.4% | · | -1806.5% | -1372.6% | -1088.4% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -1089.3% | -1384.4% | · | -1620.5% | -1340.6% | -1046.7% | · | · | · | -10062.3% | · | -60.5% | 10.3% | -769.9% | · | -226.6% | |
| ROA | -13.4% | -9.2% | · | -25.9% | -19.2% | -15.0% | · | -7.2% | -6.4% | -8.8% | · | -13.6% | 3.9% | -12.0% | · | -7.4% | |
| ROE | -16.5% | -10.9% | · | -41.3% | -28.5% | -21.1% | · | -12.3% | -12.1% | -26.2% | · | -32.5% | 9.4% | -38.3% | · | -21.7% | |
| ROIC | -9.9% | -6.4% | · | -26.3% | -19.4% | -14.2% | · | · | · | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 21.2 | 28.9 | · | 6.5 | 7.7 | 8.8 | · | · | · | · | · | 2.0 | 1.9 | 1.4 | · | 2.3 | |
| Quick Ratio | 21.0 | 28.7 | · | 6.2 | 7.3 | 8.4 | · | 4.6 | 3.3 | 2.8 | · | 1.6 | 1.6 | 1.2 | · | 2.1 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | 0.2 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | 3.4 | 0.9 | 0.8 | · | 0.0 | 0.0 | 0.0 | · | 20.8 | 18.1 | 1.4 | · | 1.4 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $15.06 | $16.23 | · | $3.49 | $4.32 | $5.04 | · | $12.32 | $14.17 | $17.76 | · | · | $0.41 | $0.21 | · | $0.48 | |
| Revenue / Share | $0.14 | $0.08 | · | $0.06 | $0.06 | $0.07 | · | $0.00 | $0.00 | · | · | · | $0.23 | · | · | · | |
| Cash Flow / Share | · | $-0.83 | · | · | · | $-0.61 | · | · | · | · | · | · | · | · | · | · | |
| Cash / Share | $13.05 | $14.42 | · | $5.73 | $6.37 | $6.86 | · | $14.67 | $14.95 | $15.43 | · | · | $0.45 | $0.53 | · | $0.65 | |
| EPS (TTM) | $-4.83 | $-4.17 | · | $-2.51 | $-5.42 | $-7.03 | · | $12.55 | $7.79 | $13.88 | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | $47M | $33M | $17M | · | $28M | |
| Net Income TTM | $-62M | $-49M | · | $-33M | $-28M | $-23M | · | $25M | $21M | $29M | · | $-28M | $-27M | $-41M | · | $-35M | |
| Market Cap | $2.20B | $1.78B | · | $695M | $249M | $308M | · | $22M | $13M | $18M | · | · | $1.31B | $5.82B | · | $6.85B | |
| P/E | -31.6 | -29.9 | · | -25.0 | -4.2 | -4.0 | · | 1.3 | 1.3 | 1.1 | · | · | · | · | · | · | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | 39.5 | 345.3 | · | 240.2 | |
| P/B | 10.1 | 7.7 | · | 18.0 | 5.2 | 5.6 | · | 1.3 | 0.7 | 0.8 | · | · | 32.4 | 376.4 | · | 191.4 | |
| P / Tangible Book | 10.1 | 7.7 | · | 18.0 | 5.2 | 5.6 | · | 1.3 | 0.7 | 0.8 | · | · | 32.4 | 376.4 | · | 191.4 | |
| P / Cash Flow | · | -164.2 | · | · | · | -45.6 | · | · | · | -2.6 | · | · | · | -529.1 | · | · | |
| Earnings Yield | -3.2% | -3.4% | · | -4.0% | -24.1% | -25.1% | · | 75.7% | 79.4% | 94.8% | · | · | · | · | · | · |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | · | · | $43M | $26M | $31M |
| Betriebsgewinnmarge % | -1490.4% | · | · | -167.8% | · |
| Nettoergebnis | $-42M | $-17M | $19M | $-33M | $-46M |
| Verwässerte EPS | $-3.71 | $-7.83 | $2.17 | · | $-0.71 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 5.2 | 7.3 | · | 2.0 | · |
| Quick Ratio | 5.1 | 7.0 | · | 1.8 | · |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | · | · | · | $-61M | · |
Institutionelle Eigentümer (13F) 210 Einreicher · $2.2B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
210
Gehaltener Wert
$2.2B
Neue Positionen
35
Geschlossene Positionen
19
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 35 (-35 vs. Vorquartal) | 19 (-3 vs. Vorquartal) | 93 (+24 vs. Vorquartal) | 45 (+15 vs. Vorquartal) | +820K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | $173.512.745 | 1.135.406 | 7,97% | Aktien |
| JENNISON ASSOCIATES LLC | $146.801.795 | 960.619 | 6,75% | Aktien |
| BlackRock, Inc. | $140.343.317 | 918.357 | 6,45% | Aktien |
| Frazier Life Sciences Management, L.P. | $134.848.368 | 882.400 | 6,20% | Aktien |
| First Light Asset Management, LLC | $117.961.911 | 771.901 | 5,42% | Aktien |
| BVF INC/IL | $102.815.615 | 672.789 | 4,72% | Aktien |
| STATE STREET CORP | $99.817.745 | 653.172 | 4,59% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $78.517.999 | 513.794 | 3,61% | Aktien |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $73.175.272 | 478.833 | 3,36% | Aktien |
| FEDERATED HERMES, INC. | $66.173.352 | 433.015 | 3,04% | Aktien |
| VANGUARD GROUP INC | $58.679.676 | 560.616 | 2,70% | Aktien |
| Woodline Partners LP | $48.522.948 | 317.517 | 2,23% | Aktien |
| ORBIMED ADVISORS LLC | $44.678.455 | 292.360 | 2,05% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $42.213.033 | 276.164 | 1,94% | Aktien |
| Siren, L.L.C. | $39.348.858 | 257.485 | 1,81% | Aktien |
| PRIMECAP MANAGEMENT CO/CA/ | $39.149.734 | 256.182 | 1,80% | Aktien |
| EVENTIDE ASSET MANAGEMENT, LLC | $35.375.385 | 231.484 | 1,63% | Aktien |
| EMERALD ADVISERS, LLC | $35.070.051 | 229.486 | 1,61% | Aktien |
| FMR LLC | $32.831.927 | 214.841 | 1,51% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $31.557.391 | 253.168 | 1,45% | Aktien |
| MPM BIOIMPACT LLC | $31.179.406 | 204.027 | 1,43% | Aktien |
| GOLDMAN SACHS GROUP INC | $30.795.370 | 201.514 | 1,42% | Aktien |
| MORGAN STANLEY | $27.725.827 | 181.428 | 1,27% | Aktien |
| First Turn Management, LLC | $23.908.689 | 156.450 | 1,10% | Aktien |
| Bellevue Group AG | $23.687.100 | 155.000 | 1,09% | Aktien |
| Caption Management, LLC | $21.394.800 | 140.000 | 0,98% | Verkaufsoption |
| EMERALD MUTUAL FUND ADVISERS TRUST | $19.843.219 | 129.847 | 0,91% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $19.707.973 | 128.962 | 0,91% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18.430.092 | 120.600 | 0,85% | Kaufoption |
| Aberdeen Group plc | $18.374.771 | 120.238 | 0,84% | Aktien |
| NORTHERN TRUST CORP | $14.853.034 | 97.193 | 0,68% | Aktien |
| NEXTBio Capital Management LP | $13.739.893 | 89.909 | 0,63% | Aktien |
| Clio Asset Management LLC | $13.194.937 | 86.343 | 0,61% | Aktien |
| NEUBERGER BERMAN GROUP LLC | $12.700.411 | 83.107 | 0,58% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.706.012 | 76.600 | 0,54% | Verkaufsoption |
| VANGUARD FIDUCIARY TRUST CO | $11.307.916 | 73.995 | 0,52% | Aktien |
| UBS Group AG | $11.083.424 | 72.526 | 0,51% | Aktien |
| Avidity Partners Management LP | $10.697.400 | 70.000 | 0,49% | Aktien |
| AWM Investment Company, Inc. | $10.608.153 | 69.416 | 0,49% | Aktien |
| SEVEN GRAND MANAGERS, LLC | $9.169.200 | 60.000 | 0,42% | Aktien |
| Clearbridge Investments, LLC | $9.068.458 | 59.341 | 0,42% | Aktien |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $8.713.159 | 69.901 | 0,40% | Aktien |
| BANK OF AMERICA CORP /DE/ | $8.336.942 | 54.554 | 0,38% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $8.140.721 | 53.270 | 0,37% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $7.979.038 | 52.212 | 0,37% | Aktien |
| Ensign Peak Advisors, Inc | $7.894.681 | 51.660 | 0,36% | Aktien |
| HSBC HOLDINGS PLC | $7.641.156 | 50.001 | 0,35% | Aktien |
| Nicholas Investment Partners, LP | $7.597.905 | 49.718 | 0,35% | Aktien |
| Balyasny Asset Management L.P. | $6.805.992 | 44.536 | 0,31% | Aktien |
| Lisanti Capital Growth, LLC | $6.567.440 | 42.975 | 0,30% | Aktien |
Aktivisten & 5%+-Eigentümer 3 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Kaupinen Wes, Wesley H. Kaupinen 2019 Irrevocable Trust dated February 28, 2019, Christine L. Kaupinen, Christine L. Kaupinen 2019 Irrevocable Trust dated February 28, 2019, Michael Christopher | 20. Dezember 2024 | 14,60% | Erste Einreichung | · | SEC |
| Biotechnology Value Fund, L.P., BVF I GP LLC, Biotechnology Value Fund II, L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., Mark N. Lampert ×2 Einreichungen | 17. August 2023 | · | Erste Einreichung | · | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP III LLC ×10 Einreichungen | 27. September 2018 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 34 Insider · 16 Führungskräfte · 19 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Kaupinen Wes | President and CEO | 5. Februar 2026 A | · | 0 | 0 | $0 |
| Stephen S. Yoder | Chief Executive Officer | 24. Februar 2023 A | 6.000 | 0 | 0 | $0 |
| Matthew E Korenberg | CFO, Treasurer | 12. Juni 2026 M | 1.000 | 0 | 0 | $0 |
| Thomas Bures | Chief Financial Officer | 24. Februar 2023 A | · | 0 | 0 | $0 |
| Allan Reine | Chief Financial Officer | 26. Februar 2019 A | 65.000 | 0 | 0 | $0 |
| Darlene M Deptula-Hicks | SVP, Chief Financial Officer | 13. Juni 2016 P | 5.000 | 0 | 0 | $0 |
| Kathleen Goin | Chief Operating Officer | 16. September 2026 M | 0 | 0 | 33 | $-5.506.479 |
| Ashley Hartmann Kline | Chief Commercial Officer | 5. Februar 2026 A | · | 0 | 0 | $0 |
| Jeffrey S Martini | Chief Scientific Officer | 5. Februar 2026 A | · | 0 | 0 | $0 |
| PALVELLA THERAPEUTICS, INC. | Chief Scientific Officer | 5. Februar 2025 A | · | 0 | 0 | $0 |
| Ahmed Mousa | Chief Business Officer | 24. Februar 2023 A | · | 0 | 0 | $0 |
| Shane Olwill | Chief Development Officer | 24. Februar 2023 A | 4.638 | 0 | 0 | $0 |
| Hitto Kaufmann | Chief Scientific Officer | 24. Februar 2023 A | · | 0 | 0 | $0 |
| Tim Demuth | Chief Medical Officer | 13. Mai 2022 P | 6.000 | 0 | 0 | $0 |
| Louis Matis | Chief Development Officer | 26. Februar 2019 A | 10.000 | 0 | 0 | $0 |
| Claude Knopf | Chief Business Officer | 28. November 2016 A | · | 0 | 0 | $0 |
| George M Jenkins | Direktor | 15. September 2026 S | 160.116 | 2 | 9 | $-3.617.215 |
| Christopher P Kiritsy | Direktor | 2. September 2026 M | 250 | 0 | 1 | $-49.141 |
| Matthew Pauls | Direktor | 29. Juni 2026 A | · | 0 | 0 | $0 |
| Tadd S. Wessel | Direktor | 10. Juni 2026 A | · | 0 | 0 | $0 |
| John Doux | Direktor | 10. Juni 2026 A | · | 0 | 0 | $0 |
| Todd C Davis | Direktor | 10. Juni 2026 A | · | 0 | 0 | $0 |
| Elaine J Heron | Direktor | 10. Juni 2026 A | 47.812 | 1 | 0 | $300.000 |
| James A Geraghty | Direktor | 12. Dezember 2024 D | 0 | 0 | 0 | $0 |
| Maya R. Said | Direktor | 21. Juni 2023 A | · | 0 | 0 | $0 |
| Ann Barbier | Direktor | 21. Juni 2023 A | · | 0 | 0 | $0 |
| Michael Richman | Direktor | 21. Juni 2023 A | · | 0 | 0 | $0 |
| Peter A Kiener | Direktor | 21. Juni 2023 A | · | 0 | 0 | $0 |
| Matthew L Sherman | Direktor | 21. Juni 2023 A | · | 0 | 0 | $0 |
| Jean-Pierre Bizzari | Direktor | 25. Januar 2020 A | · | 0 | 0 | $0 |
| Steven Prelack | Direktor | 25. Januar 2019 A | · | 0 | 0 | $0 |
| Julian Adams | Direktor | 25. Januar 2018 A | · | 0 | 0 | $0 |
| Chau Quang Khuong | Direktor | 25. Oktober 2017 A | 65.398 | 0 | 0 | $0 |
| Aquilo Capital Management, LLC | 10%-Eigentümer | 21. Juli 2020 S | 3.675.530 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 21 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,86% | 2.856 NS | 31. Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,39% | 13.887 NS | 31. Juli 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,18% | 22.955 SH | 19. August 2026 | Täglich |
| PWS · Pacer Funds Trust | 0,11% | 190 NS | 31. Juli 2026 | N-PORT |
| IWO · iShares Trust | 0,11% | 103.168 SH | 11. September 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,10% | 11.762 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,05% | 280.820 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,05% | 63.184 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,05% | 5.240 NS | 31. Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,02% | 1.583 SH | 11. September 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 4.864 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 113.556 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,02% | 30.157 SH | 19. August 2026 | Täglich |
| WSML · iShares Trust | 0,02% | 674 SH | 10. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 3.420 SH | 3. September 2026 | Täglich |
| ITOT · iShares Trust | 0,00% | 14.740 SH | 11. September 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,00% | 218 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 388.390 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 904 SH | 19. August 2026 | Täglich |
| ISCB · iShares Trust | · | 450 SH | 11. September 2026 | Täglich |
| ISCV · iShares Trust | · | 1.075 SH | 11. September 2026 | Täglich |
PVLA Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 22 Analysten
KAUF
Median-Ziel
$232.00
+75,1%
6 27,3%
Starker Kauf
15 68,2%
Kauf
1 4,5%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
15 Analysten · 2026-09-28Mittelwert-Ziel $230.53 +74,0%
← Unter allen Zielen
Aktueller Preis $132.47
Tief$205.00
Mittelwert$230.53
Hoch$270.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | · |
| GENB | · | · | · | · | · | · |
| NTLA | $1.05B | -2.4 | 16.9% | -609.8% | -59.5% | · |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 4, 2026